EVISTA Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Evista, and when can generic versions of Evista launch?
Evista is a drug marketed by Lilly and is included in one NDA.
The generic ingredient in EVISTA is raloxifene hydrochloride. Eighteen suppliers are listed for this compound. Additional details are available on the raloxifene hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Evista
A generic version of EVISTA was approved as raloxifene hydrochloride by TEVA PHARMS USA on March 4th, 2014.
US Patents and Regulatory Information for EVISTA
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Lilly | EVISTA | raloxifene hydrochloride | TABLET;ORAL | 020815-001 | Dec 9, 1997 | AB | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for EVISTA
See the table below for patents covering EVISTA around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Austria | 14429 | ⤷ Start Trial | |
| Austria | 17243 | ⤷ Start Trial | |
| Australia | 555658 | ⤷ Start Trial | |
| Australia | 8226582 | ⤷ Start Trial | |
| Bulgaria | 37378 | METHOD FOR PREPARING ACYLATED BENZOTHIOPHENS | ⤷ Start Trial |
| Canada | 1167036 | SYNTHESE DE BENZOTHIOPHENES ACYLES (SYNTHESIS OF ACYLATED BENZOTHIOPHENES) | ⤷ Start Trial |
| Canada | 1167037 | PROCEDE D'OBTENTION DE 3-(4-AMINOETHOXYBENZOYL) BENZO (B) THIOPHENES (PROCESS FOR PREPARING 3-(4-AMINOETHOXYBENZOYL) BENZO (B) THIOPHENES) | ⤷ Start Trial |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for EVISTA
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0584952 | SPC/GB98/048 | United Kingdom | ⤷ Start Trial | PRODUCT NAME: RALOXIFENE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REGISTERED: UK EU/1/98/073/001 19980805; UK EU/1/98/073/002 19980805; UK EU/1/98/073/003 19980805; UK EU/1/98/073/004 19980805; UK EU/1/98/074/001 19980805; UK EU/1/98/074/002 19980805; UK EU/1/98/074/003 19980805; UK EU/1/98/074/004 19980805 |
| 0584952 | 1/1999 | Austria | ⤷ Start Trial | PRODUCT NAME: RALOXIFEN ODER DESSEN PHARMEZEUTISCH ANNEHMBARE SALZE; REGISTRATION NO/DATE: EU/1/98/073/001- EU/1/98/073/004 19980805 |
| 0584952 | 99C0004 | Belgium | ⤷ Start Trial | PRODUCT NAME: ESTRADIOL, HEMIHYDRATE, NORETHISTERONE, ACETATE; NAT. REGISTRATION NO/DATE: NL 23753 19981210; FIRST REGISTRATION: SE - 14 007 19980306 |
| 0584952 | 980044 | Netherlands | ⤷ Start Trial | PRODUCT NAME: RALOXIFENE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAAR DBAAR ZOUT, IN HET BIJZONDER HET HYDROCHLORIDE; REGISTRATION NO/DATE: EU/1/98/073/001 - EU/1/98/073/004, EU/1/98/074/001 - EU/1/98/074/004 19980805 EU/1/98/073/001 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Generic Entry Opportunies 2026 - 2027
NCE-1 Patent Challenge Dates 2026 - 2027
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2026, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch